Gene expression profiles in prostate cancer: identification of candidate non-invasive diagnostic markers

Actas Urol Esp. 2014 Apr;38(3):143-9. doi: 10.1016/j.acuro.2013.07.012. Epub 2013 Oct 25.
[Article in English, Spanish]

Abstract

Objective: To analyze gene expression profiles of prostate cancer (PCa) with the aim of determining the relevant differentially expressed genes and subsequently ascertain whether this differential expression is maintained in post-prostatic massage (PPM) urine samples.

Material and methods: Forty-six tissue specimens (36 from PCa patients and 10 controls) and 158 urine PPM-urines (113 from PCa patients and 45 controls) were collected between December 2003 and May 2007. DNA microarrays were used to identify genes differentially expressed between tumour and control samples. Ten genes were technically validated in the same tissue samples by quantitative RT-PCR (RT-qPCR). Forty two selected differentially expressed genes were validated in an independent set of PPM-urines by qRT-PCR.

Results: Multidimensional scaling plot according to the expression of all the microarray genes showed a clear distinction between control and tumour samples. A total of 1047 differentially expressed genes (FDR≤.1) were indentified between both groups of samples. We found a high correlation in the comparison of microarray and RT-qPCR gene expression levels (r=.928, P<.001). Thirteen genes maintained the same fold change direction when analyzed in PPM-urine samples and in four of them (HOXC6, PCA3, PDK4 and TMPRSS2-ERG), these differences were statistically significant (P<.05).

Conclusion: The analysis of PCa by DNA microarrays provides new putative mRNA markers for PCa diagnosis that, with caution, can be extrapolated to PPM-urines.

Keywords: Cáncer de próstata; DNA microarrays; Expresión génica; Gene expression; Marcadores moleculares; Microarrays de ADN; Molecular markers; Prostate cancer; RT-PCR cuantitativa; RT-PCR quantitative.

Publication types

  • Research Support, Non-U.S. Gov't
  • Validation Study

MeSH terms

  • Adenocarcinoma / chemistry
  • Adenocarcinoma / diagnosis
  • Adenocarcinoma / genetics*
  • Adenocarcinoma / pathology
  • Adenocarcinoma / urine
  • Aged
  • Antigens, Neoplasm / biosynthesis
  • Antigens, Neoplasm / genetics
  • Biomarkers, Tumor / analysis
  • Biomarkers, Tumor / biosynthesis
  • Biomarkers, Tumor / genetics*
  • Biomarkers, Tumor / urine
  • Gene Expression Profiling*
  • Homeodomain Proteins / biosynthesis
  • Homeodomain Proteins / genetics
  • Humans
  • Male
  • Middle Aged
  • Neoplasm Grading
  • Neoplasm Proteins / analysis
  • Neoplasm Proteins / biosynthesis
  • Neoplasm Proteins / genetics*
  • Neoplasm Staging
  • Oligonucleotide Array Sequence Analysis
  • Oncogene Proteins, Fusion / biosynthesis
  • Oncogene Proteins, Fusion / genetics
  • Organ Size
  • Prostate / chemistry
  • Prostate / pathology
  • Prostatic Neoplasms / chemistry
  • Prostatic Neoplasms / diagnosis
  • Prostatic Neoplasms / genetics*
  • Prostatic Neoplasms / pathology
  • Prostatic Neoplasms / urine
  • Protein Serine-Threonine Kinases / biosynthesis
  • Protein Serine-Threonine Kinases / genetics
  • Pyruvate Dehydrogenase Acetyl-Transferring Kinase
  • RNA, Messenger / analysis*
  • RNA, Messenger / urine
  • RNA, Neoplasm / analysis*
  • RNA, Neoplasm / urine
  • Reverse Transcriptase Polymerase Chain Reaction
  • Subtraction Technique

Substances

  • Antigens, Neoplasm
  • Biomarkers, Tumor
  • HOXC6 protein, human
  • Homeodomain Proteins
  • Neoplasm Proteins
  • Oncogene Proteins, Fusion
  • PDK4 protein, human
  • Pyruvate Dehydrogenase Acetyl-Transferring Kinase
  • RNA, Messenger
  • RNA, Neoplasm
  • TMPRSS2-ERG fusion protein, human
  • prostate cancer antigen 3, human
  • Protein Serine-Threonine Kinases